Scientists from the Center for Genetic Engineering and Biotechnology (CIGB) together with researchers from the Cuban health system have been developing for a decade a promising vaccine candidate HeberSaVax to guarantee the survival of patients with liver cancer or hepatocarcinoma, a pathology that annually causes more than half a million deaths worldwide.
Read more HeberSaVax: Another achievement of Cuban biotechnologyPage 133 of 465